When Harm in the Hospital Follows You Home
ProPublica Q&A with a professor who specializes in the aftermath of medical harm to patients.
View ArticleMedicare Drug Program Fails to Monitor Prescribers, Putting Seniors and...
ProPublica's "The Prescribers" series: "Prescription data obtained by ProPublica shows widespread use of antipsychotics, narcotics and other drugs dangerous for older adults, but Medicare officials say...
View ArticleBig Pharma’s Big Fines
Summary of large settlements big pharma has paid for fraudulent marketing.
View Article‘Let the Crime Spree Begin’: How Fraud Flourishes in Medicare’s Drug Plan
ProPublica identified scores of doctors whose prescribing in Medicare’s drug program bore the hallmarks of fraud
View ArticleConsumer Reports: How safe is your baby’s medicine bottle?
Infant Tylenol and other liquid acetaminophen products have a new safety feature. Consumer Reports put it to the test.
View ArticleIn A Major Shift, Medicare Wants Power to Ban Harmful Prescribers
ProPublica reports that Medicare has issued a proposed rule that would give the agency the "authority to kick out physicians and other providers who engage in abusive prescribing. It could also take...
View ArticlePatient Harm: When An Attorney Won’t Take Your Case
ProPublica reports on an Emory study that found three out of four medical malpractice attorneys reject more than 90 percent of the cases they screen. Most harmed patients get no legal representation,...
View ArticleReporting Recipe: Dollars for Docs
With more data on relationships between doctors and drug companies soon to be released, here are some ways journalists can use this information.
View ArticleProPublica: Our First Dive Into the New Open Payments System
The government’s data on payments to doctors and hospitals by drug and device makers is incomplete and hard to penetrate – but here’s a first look. (Charles Ornstein, ProPublica)
View ArticleProPublica Analysis: Government’s New Doctor Payments Website Worthy of a Recall
Health reporter Charles Ornstein takes a test drive using the federal government’s new website for drug and device payments. He finds it virtually unusable.
View Article
